JP7290627B2 - Ａｔｒキナーゼの複素環式阻害剤 - Google Patents

Ａｔｒキナーゼの複素環式阻害剤 Download PDF

Info

Publication number
JP7290627B2
JP7290627B2 JP2020508534A JP2020508534A JP7290627B2 JP 7290627 B2 JP7290627 B2 JP 7290627B2 JP 2020508534 A JP2020508534 A JP 2020508534A JP 2020508534 A JP2020508534 A JP 2020508534A JP 7290627 B2 JP7290627 B2 JP 7290627B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
membered heterocycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531447A (ja
JP2020531447A5 (enExample
Inventor
エミリア ディ フランチェスコ マリア
ジョーンズ フィリップ
ローレンス キャロル クリストファー
ブライアント クロス ジェーソン
カン ジジュン
ギャレット ジョンソン マイケル
ライブリー サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chempartner Corp
University of Texas System
Original Assignee
Chempartner Corp
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chempartner Corp, University of Texas System filed Critical Chempartner Corp
Publication of JP2020531447A publication Critical patent/JP2020531447A/ja
Publication of JP2020531447A5 publication Critical patent/JP2020531447A5/ja
Application granted granted Critical
Publication of JP7290627B2 publication Critical patent/JP7290627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020508534A 2017-08-17 2018-08-17 Ａｔｒキナーゼの複素環式阻害剤 Active JP7290627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546944P 2017-08-17 2017-08-17
US62/546,944 2017-08-17
PCT/US2018/046937 WO2019036641A1 (en) 2017-08-17 2018-08-17 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (3)

Publication Number Publication Date
JP2020531447A JP2020531447A (ja) 2020-11-05
JP2020531447A5 JP2020531447A5 (enExample) 2021-09-24
JP7290627B2 true JP7290627B2 (ja) 2023-06-13

Family

ID=65361058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508534A Active JP7290627B2 (ja) 2017-08-17 2018-08-17 Ａｔｒキナーゼの複素環式阻害剤

Country Status (5)

Country Link
US (1) US10800774B2 (enExample)
EP (1) EP3668839B1 (enExample)
JP (1) JP7290627B2 (enExample)
CN (1) CN111886224B (enExample)
WO (1) WO2019036641A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
EP3651768B1 (en) 2017-07-13 2023-12-20 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
CA3074719A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc Substituted pyrrolopyridines as atr inhibitors
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
EP3873905A4 (en) 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING COMPOUNDS AND THEIR USE AS KINASE ATR INHIBITORS
EP3967694A4 (en) * 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR
PL4011881T3 (pl) * 2019-08-06 2025-04-07 Wuxi Biocity Biopharmaceutics Co., Ltd. Postacie krystaliczne inhibitora atr i ich zastosowanie
KR20230012586A (ko) * 2020-05-29 2023-01-26 썬전 링팡 바이오테크 컴퍼니 리미티드 플루오로 피롤로 피리딘계 화합물 및 이의 용도
JP7774621B2 (ja) * 2020-10-16 2025-11-21 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド 三複素環誘導体、その医薬組成物及び使用
CN116178366B (zh) * 2021-11-26 2025-03-18 无锡瓴方生物医药科技有限公司 氟代吡啶并吡咯类化合物的晶型及其制备方法
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527464A (ja) 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
JP2010503650A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のための、ｐｉ３ｋおよびｍｔｏｒ阻害剤としての２−ベンズイミダゾリル−６−モルホリノ−４−ピペリジン−４−イルピリミジン誘導体
JP2012513388A (ja) 2008-12-22 2012-06-14 アストラゼネカ アクチボラグ 癌を処置するためのピリミジンインドール誘導体
JP2012521983A (ja) 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
JP2013528204A (ja) 2010-06-11 2013-07-08 アストラゼネカ アクチボラグ モルホリノピリミジンおよび治療におけるそれらの使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49570B1 (en) 1979-03-30 1985-10-30 Rhone Poulenc Ind 2-(pyrid-2-yl)tetrahydrothiophene derivatives
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2146981A1 (en) * 2007-04-12 2010-01-27 F. Hoffmann-Roche AG Pharmaceutical compounds
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
EA201000092A1 (ru) * 2007-07-09 2010-06-30 Астразенека Аб Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) * 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
MX389198B (es) 2014-10-13 2025-03-20 Atrin Pharmaceuticals LLC Inhibidores de proteína-cinasas relacionados a ataxia-telengiectasia y rad3 (atr).
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
CN109153646B (zh) 2016-05-24 2022-08-02 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的吡啶二甲酰胺衍生物
CA3026149A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
EP3651768B1 (en) 2017-07-13 2023-12-20 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527464A (ja) 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
JP2010503650A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のための、ｐｉ３ｋおよびｍｔｏｒ阻害剤としての２−ベンズイミダゾリル−６−モルホリノ−４−ピペリジン−４−イルピリミジン誘導体
JP2012513388A (ja) 2008-12-22 2012-06-14 アストラゼネカ アクチボラグ 癌を処置するためのピリミジンインドール誘導体
JP2012521983A (ja) 2009-03-27 2012-09-20 パトフワイ トヘラペウトイクス インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
JP2013528204A (ja) 2010-06-11 2013-07-08 アストラゼネカ アクチボラグ モルホリノピリミジンおよび治療におけるそれらの使用

Also Published As

Publication number Publication date
WO2019036641A1 (en) 2019-02-21
CN111886224A (zh) 2020-11-03
US10800774B2 (en) 2020-10-13
EP3668839B1 (en) 2023-04-12
JP2020531447A (ja) 2020-11-05
US20190055240A1 (en) 2019-02-21
EP3668839A1 (en) 2020-06-24
EP3668839A4 (en) 2021-03-31
CN111886224B (zh) 2024-07-23

Similar Documents

Publication Publication Date Title
JP7290627B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
AU2019263294B2 (en) Substituted heterocyclic inhibitors of PTPN11
US11434233B2 (en) Heterocyclic inhibitors of ATR kinase
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
JP7341156B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
HK40028148B (en) Heterocyclic inhibitors of atr kinase
HK40028148A (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230601

R150 Certificate of patent or registration of utility model

Ref document number: 7290627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150